This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Muhl, E. Articles by Bruch, H.-P. Search for Related Content PubMed Articles by Muhl, E. Articles by Bruch, H.-P. Social Bookmarking                         What's this?

Therapy and Monitoring of Heparin-Induced Thrombocytopenia Type II in Critically Ill Patients During Continuous Venovenous Hemodiafiltration: Comparison of aPTT and Ecarin Clotting Time for Monitoring of r-Hirudin Therapy

Department of Surgery, Luebeck Medical University, Luebeck, Germany, elke.muhl{at}medinf.mu-luebeck.de

Hans-Joachim Siemens, MD

Department of Internal Medicine, Luebeck Medical University, Luebeck, Germany

Peter Kujath, MD

Department of Surgery, Luebeck Medical University, Luebeck, Germany

Hans-Peter Bruch, MD

Department of Surgery, Luebeck Medical University, Luebeck, Germany

We conducted a survey of therapy, complications, and monitoring of heparin-induced thrombocytopenia (HIT) type II in critically ill patients during continuous venovenous hemodiafiltration (CVVHDF). We also compared activated partial thromboplastin time (aPTT) and ecarin clotting time (ECT) for monitoring recombinant (r)-hirudin therapy. Six patients with HIT type II were treated with r-hirudin and were on CVVHDF due to acute renal failure (blood flow rate 90 ml/hr, dialysate flow rate 1 L/hr, substitution 1 L/hr predilution, acrylonitrile membrane 0.9 m²). The mean duration of CVVHDF was 6.2 ± 3.6 days (range 3-17 days). Diagnosis of HIT was established 5.0 ± 1.5 days (range 3-8 days) after a decrease in the platelet count. Three of six patients had other possible reasons for thrombocytopenia apart from HIT, such as massive transfusion, sepsis, or liver cirrhosis. Three thromboembolic events occurred before the diagnosis of HIT was established, none of them during treatment of HIT with r-hirudin. In all patients the platelet count doubled or increased up to 100/nl within 2.5 ± 0.5 days. The dose-response relationship of r-hirudin and aPTT was not satisfactory (r = 0.371). In patients receiving CVVHDF with one of two different doses of r-hirudin (1 mg/hr versus 2 mg/hr), there was no difference in aPTT (p < 0.77) but a significant difference in ECT (p < 0.001). The correlation between r-hirudin dose and ECT was r = 0.654 (p < 0.0001). r-Hirudin was safe and effective in the treatment of HIT type II in critically ill patients during CVVHDF. ECT seems to be superior to aPTT for monitoring r-hirudin therapy because it correlates better with the concentrations of r-hirudin.

Journal of Intensive Care Medicine, Vol. 17, No. 1, 34-40 (2002)
DOI: 10.1177/088506660201700103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?